• EIQ.XA is trading at A$1.70 (+37.37%) following a sharp session, likely fueled by recent appointments aimed at accelerating its U.S. commercial growth and FDA initiatives.
  • Echo IQ Limited announced on June 24, 2026, the appointment of Matthew Dodds as Chief Financial Officer and Dr. Vinod Thourani as Clinical Advisor to bolster its executive leadership and clinical advisory network.
  • These strategic hires are set to support the expansion of its EchoSolv platform in the U.S. healthcare market and advance crucial regulatory processes with the FDA.